Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ExportDeal #MexicoMarket #BotulinumToxin #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=102961
Daewoong Pharmaceutical Exports Nabota to Mexico in 29.5 Billion Won Deal
Daewoong Pharmaceutical Co., Ltd. has signed a 29.5 billion won ($22.2 million) export deal with M8 (Moksha8) to supply its botulinum toxin Nabota to Mexico, expanding its reach across Latin America's top five aesthetic markets and highlighting significant growth potential in the region.
Daewoong Pharmaceutical's Nabota Completes Entry into 10 Middle Eastern Countries
Daewoong Pharmaceutical has expanded its botulinum toxin Nabota to 10 Middle Eastern countries, securing new export deals with Iraq and Bahrain as part of its broader MENA strategy.
Daewoong Pharmaceutical signed a 34.1 billion won ($25.8 million) export deal with Colombia's Valentech Pharma for Nabota, aiming for a 30% market share in the Latin American aesthetics market within five years.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ValentechPharma #LatinAmericaMarket #BotulinumToxinExport #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=78621
Daewoong Pharmaceutical Signs 34.1 Billion Won Nabota Export Deal with Colombia, Targets Latin American Market
Daewoong Pharmaceutical signed a 34.1 billion won ($25.8 million) export deal with Colombia's Valentech Pharma for Nabota, aiming for a 30% market share in the Latin American aesthetics market within five years.
Daewoong Pharmaceutical has voluntarily withdrawn its application for Nabota's 100-unit product approval in China, aiming to resubmit with expanded dosage options to meet regulatory and market demands.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ChinaApproval #BotulinumToxin #ProductWithdrawal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=74601
Daewoong Pharmaceutical Voluntarily Withdraws Nabota Product Application in China
Daewoong Pharmaceutical has voluntarily withdrawn its application for Nabota's 100-unit product approval in China, aiming to resubmit with expanded dosage options to meet regulatory and market demands.
Yonhap Infomax News